Lysten Global Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 15-07-2024
- Paid Up Capital ₹ 1.00 M
as on 15-07-2024
- Company Age 9 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 5.50 M
as on 15-07-2024
- Revenue -21.40%
(FY 2020)
- Profit 54.79%
(FY 2020)
- Ebitda 53.55%
(FY 2020)
- Net Worth -14.35%
(FY 2020)
- Total Assets -13.65%
(FY 2020)
About Lysten Global Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company has closed loans amounting to ₹5.50 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Nitin Jadhav, Sachin Patil, Shilpa Jadhav, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24239PN2015PTC156013
- Company No.
156013
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Jul 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Kolhapur, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Lysten Global Pharmaceuticals?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nitin Jadhav  | Director | Current | |
| Sachin Patil | Director | Current | |
| Shilpa Jadhav | Director | Current | |
| Vijay Patil | Director | 04-Nov-2015 | Current |
| Bahubali Borgave | Director | 31-Jul-2015 | Current |
| Vikas Patil | Director | Current |
Financial Performance of Lysten Global Pharmaceuticals.
Lysten Global Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 21.4% decrease. The company also saw a substantial improvement in profitability, with a 54.79% increase in profit. The company's net worth observed a substantial decline by a decrease of 14.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lysten Global Pharmaceuticals?
In 2020, Lysten Global Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Bank Creation Date: 31 Jan 2017 | ₹5.50 M | Satisfied |
How Many Employees Work at Lysten Global Pharmaceuticals?
Lysten Global Pharmaceuticals has a workforce of 36 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lysten Global Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lysten Global Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
